Sitagliptin (Januvia) is a drug used in the treatment of:

Sitagliptin has no therapeutic effect on schizophrenia, a serious mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Medications for schizophrenia typically include antipsychotics, which target neurotransmitter imbalances, a mechanism unrelated to the action of sitagliptin.

Parkinson's disease is a neurodegenerative disorder that primarily affects movement control due to dopamine deficiency. Treatments for Parkinson's involve dopaminergic agents and other classes of medications aimed at alleviating motor symptoms, which are entirely different from the glucose-regulating function of sitagliptin.

Type 1 diabetes is an autoimmune condition where the body fails to produce insulin due to the destruction of pancreatic beta cells. Treatment primarily involves insulin replacement therapy, as sitagliptin is not suitable for managing type 1 diabetes due to its mechanism of action, which relies on the presence of some insulin production.